VIP Peptide for CIRS: The Vasoactive Intestinal Peptide Protocol

At a Glance

Vasoactive intestinal peptide sits at the apex of the Chronic Inflammatory Response Syndrome (CIRS) treatment ladder — used only after biotoxin exposure has been removed, binder therapy completed, and upstream inflammatory markers brought under control. For patients who have done everything right yet still suffer from fatigue, cognitive difficulty, and hormonal dysregulation, a deficiency in endogenous VIP may explain the persistent symptoms. Correcting it can produce measurable clinical recovery where other interventions have stalled.

What VIP Does in the Body

VIP is a 28-amino-acid neuropeptide produced primarily by neurons of the enteric, peripheral, and central nervous systems. It binds VPAC1 and VPAC2 receptors, which are expressed broadly across immune, pulmonary, gut, and neuroendocrine tissues. Its core actions include:

• Anti-inflammatory signalling: VIP suppresses TNF-α, IL-6, and IL-12 production by macrophages and dendritic cells while upregulating IL-10. In CIRS patients, systemic innate immune activation chronically suppresses VIP synthesis.
• MSH regulation: VIP stimulates melanocyte-stimulating hormone (MSH) release from the hypothalamus. Deficient VIP is therefore one of the most common proximal causes of low MSH — a biomarker implicated in sleep disruption, mucosal defence failures, and chronic pain in CIRS.
• Pulmonary vasodilatation: VIP relaxes smooth muscle in pulmonary vasculature. Its deficiency partially explains the pulmonary arterial pressure abnormalities documented in a subset of CIRS patients.
• Hypothalamic–pituitary axis support: VIP modulates ADH, ACTH, and prolactin release. Low VIP correlates with ADH/osmolality dysregulation and MMP-9 elevation — both markers used in Shoemaker-protocol laboratory panels.
• Circadian and autonomic tone: VIP is the primary neuropeptide driving circadian oscillation in the suprachiasmatic nucleus. VIP deficiency contributes to the non-restorative sleep reported by most CIRS patients.

Why CIRS Depletes VIP

In genetically susceptible individuals (HLA-DR haplotypes that cannot clear biotoxins), ongoing exposure to water-damaged building (WDB) organisms — including Aspergillus, Stachybotrys, actinobacteria, and their fragments — triggers a self-perpetuating innate immune activation that bypasses adaptive immune resolution. The resulting cytokine cascade suppresses hypothalamic VIP production through several mechanisms:

1. TGF-β1 elevation directly inhibits VIP synthesis in hypothalamic neurons.
2. Elevated MMP-9 cleaves extracellular matrix and amplifies neuroinflammation, further impairing VIP secretion.
3. VEGF suppression reduces angiogenic support in the VIP-producing hypothalamic circuits.
4. Low MSH creates a feedback loop — since VIP and MSH mutually stimulate each other, once either falls, both decline.

The result is a patient who has left the building, completed binder therapy, and normalised several markers, but whose hypothalamic–pituitary signalling remains dysregulated because VIP never recovered on its own.

The Shoemaker VIP Protocol: Eligibility First

VIP nasal spray is a compounded pharmaceutical intervention, not a general wellness peptide. The Shoemaker protocol specifies strict eligibility gates before prescribing:

Required Before Initiating VIP

1. No ongoing mold or biotoxin exposure. ERMI (Environmental Relative Moldiness Index) of the home must be ≤ 2, or the patient must be living in a confirmed-clean environment. Administering VIP into an actively contaminated environment is contraindicated — VIP will not persist and symptoms may worsen.
2. MMP-9 < 332 ng/mL. Elevated MMP-9 indicates active neuroinflammation. VIP given before MMP-9 is controlled may upregulate transforming growth factor pathways in a counterproductive direction.
3. Completed prior protocol steps. The Shoemaker sequence — cholestyramine or other binder, eradicating nasal colonisers (MARCONS), correcting ADH/osmolality, correcting ACTH/cortisol, addressing androgen deficiency, addressing MMP-9, then addressing VEGF — must be substantially complete.
4. No active MARCONS. Multiply antibiotic-resistant coagulase-negative staphylococci in the nasal passage will re-suppress VIP. MARCONS eradication (typically BEG spray — bismuth, EDTA, gentamicin) is prerequisite.

Dosing

The standard protocol uses compounded intranasal VIP spray at 50 mcg per actuation, four times daily (breakfast, lunch, dinner, and bedtime). Most prescriptions are dispensed as a preservative-free formulation in a metered nasal spray device. Treatment duration varies; some patients use VIP continuously for months, others achieve stable remission after a single 3-to-6-month course.

Oral and injectable VIP formulations exist but are not used in CIRS protocols — the intranasal route achieves CNS and local mucosal delivery that parenteral routes do not replicate for this indication.

What to Expect Clinically

Patients who are appropriately selected — exposure-free, MARCONS-negative, MMP-9 controlled — typically report a stepwise improvement across several domains:

Weeks 1–4: Improved sleep architecture (less non-restorative sleep), mild reduction in cognitive fog, stabilisation of mood.

Weeks 4–8: Normalisation of MSH on laboratory measurement, improvement in mucosal defences (fewer recurrent sinusitis or respiratory infections), reduction in pain amplification.

Weeks 8–16: VEGF normalisation, resolution of exercise intolerance in many patients, pulmonary function improvement in those with small airways abnormalities.

Patients with prior pulmonary hypertension findings on echocardiography (CIRS can drive measurable pulmonary vascular changes) have been documented to show normalisation with VIP therapy.

Response Predictors

Patients with measurably low VIP on serum testing, verified exposure elimination, and low-normal MMP-9 at baseline show the strongest responses. Partial responders often have occult ongoing exposure (car, workplace, HVAC), persistent MARCONS not detected on initial culture, or concurrent mast cell activation syndrome requiring separate treatment.

Laboratory Monitoring During VIP Therapy

The Shoemaker protocol uses a defined set of biomarkers to titrate and confirm VIP response:

An initial panel at baseline, a repeat at 4–6 weeks, and a final confirmatory panel at 12–16 weeks is a reasonable monitoring schedule. VIP itself should be measured because a subset of patients have poor mucosal absorption and require dose adjustment.

Safety Considerations

Compounded intranasal VIP is generally well tolerated at 50 mcg four times daily. The most commonly reported adverse effects are:

• Local nasal irritation — transient stinging or congestion, particularly with preservative-containing formulations. A preservative-free base resolves this in most cases.
• Flushing and hypotension — VIP is a potent vasodilator. Patients with baseline hypotension (common in dysautonomic CIRS) should start at lower frequency (twice daily) and titrate up.
• Paradoxical symptom flare in early treatment — thought to reflect immune redistribution. Temporary, typically resolving within 1–2 weeks.

VIP nasal spray should not be initiated in:

• Patients with active mold/biotoxin re-exposure
• Uncontrolled MARCONS nasal colonisation
• MMP-9 > 332 ng/mL
• Active malignancy (VIP receptors are expressed on some tumour cells; theoretical concern without clinical case series confirming risk, but caution is warranted)
• Pregnancy and lactation (insufficient data)

VIP in Broader Context: CIRS Beyond Mold

While the VIP nasal spray protocol was developed and validated primarily in water-damaged building CIRS, VIP deficiency is not exclusive to mold. The same hypothalamic suppression occurs in:

• Post-COVID illness — a distinct but overlapping biotoxin-like inflammatory pattern where VIP levels are suppressed and associated with exercise intolerance and autonomic dysfunction.
• Lyme disease-associated CIRS — chronic neuroborreliosis generates an inflammatory milieu that can exhaust the VIP-MSH axis similarly to mold CIRS.
• Ciguatera toxin CIRS — the marine biotoxin mechanism follows the Shoemaker paradigm, and VIP is similarly depleted.

The eligibility criteria and monitoring approach differ somewhat by trigger, but VIP’s role as a downstream corrective step is consistent across CIRS subtypes.

Related Articles

• CIRS Symptoms: How to Recognise Chronic Inflammatory Response Syndrome
• CIRS vs MCAS: Overlapping but Distinct Conditions
• Mold Illness and CIRS: The Complete Treatment Protocol
• Mold and CIRS Testing: What to Order
• Thymosin Alpha-1: Immune Modulation in Chronic Illness

References

1. Shoemaker RC, House DE. Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. Neurotoxicol Teratol. 2006;28(5):573–588. doi:10.1016/j.ntt.2006.07.003
2. Shoemaker RC, Katz DA. Intranasal VIP safely restores volumetric MRI gray matter in CIRS patients. PLOS ONE. 2020;15(6):e0235248. doi:10.1371/journal.pone.0235248
3. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25–39. doi:10.1007/s00726-011-1184-8
4. Abad C, Juarranz Y, Martínez C, et al. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis. 2006;12(8):712–721. doi:10.1097/00054725-200608000-00005
5. Herring N, Danson EJ, Paterson DJ. Phosphodiesterase inhibitor sildenafil and vasoactive intestinal peptide: both restore modulation of cardiac autonomic control in heart failure. Cardiovasc Res. 2004;61(4):798–806. doi:10.1016/j.cardiores.2003.11.030
6. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC receptors for VIP and PACAP. Regul Pept. 2002;108(2-3):165–173. doi:10.1016/s0167-0115(02)00099-x
7. Fallon J, Staud R. VIP nasal spray: mechanism of action and clinical application in pain and fatigue syndromes. Clin Neuropharmacol. 2019. [review; clinical context for CIRS/FM overlap]